Featured news

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

NEWS

  • Media

The Times Magazine : Brenus Pharma Secures $25 Million to Propel Clinical Trials for Precision Cancer Vaccines

Read more

NEWS

  • Media

EU Startup – Lyon-based Brenus Pharma raises €22.2 million for precision cancer vaccines

Read more

NEWS

  • Media

BMF Business (FR) French Tech : Vaccins, futur de la lutte contre le cancer ?

Read more

NEWS

  • Media

Les Echos (FR) – Brenus Pharma réunit 22 millions pour lancer les essais cliniques de son vaccin anticancer

Read more

NEWS

  • Team

It’s a wrap San Diego! #BIO2024

Read more

NEWS

  • Events

Onco Startup Summit → Financements Non-dilutifs : “Comment naviguer à travers les possibilités et faire les bons choix”

Read more

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

More about Haptenization & STC immunogenicity
Back to the page

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)
Back to the page

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens

More about STC Antigenicity
Back to the page